Expert on Studies of the PSA Test in Prostate Cancer

Andrew Vickers, PhD
Published Online: Thursday, May 18, 2017



Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center discusses studies of the controversial prostate-specific antigen (PSA) test for patients with prostate cancer.

Going back to Swedish data, it has been determined that a midlife PSA test is strongly predictive of long-term risk of aggressive prostate cancer, but a PSA test is not a beneficial test for prostate cancer, explains Vickers.

Studies have also tried to determine how much getting a PSA test advances the time of when a patient has cancer compared to when they show up to the clinic and are diagnosed.
 


Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center discusses studies of the controversial prostate-specific antigen (PSA) test for patients with prostate cancer.

Going back to Swedish data, it has been determined that a midlife PSA test is strongly predictive of long-term risk of aggressive prostate cancer, but a PSA test is not a beneficial test for prostate cancer, explains Vickers.

Studies have also tried to determine how much getting a PSA test advances the time of when a patient has cancer compared to when they show up to the clinic and are diagnosed.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x